Method of predicting patient prognosis using rare cells

Patent metadata

Field	Value
Publication number	US-11371982-B2
Application number	US-201716070706-A
Country	US
Kind code	B2
Filing date	Jan 19, 2017
Priority date	Jan 19, 2016
Publication date	Jun 28, 2022
Grant date	Jun 28, 2022

Abstract

The purpose of the present invention is to provide a method for accurately predicting a cancer patient prognosis based on a count of desired cells for which expression of a leukocyte marker and an epithelial marker is hardly exhibited by detecting those cells. Provided is a method for diagnosing an overall survival prognosis for a patient suffering from cancer, the method including: a step of obtaining a concentrated solution containing desired cells by pre-treating a biological sample obtained from the patient; a step of optically detecting the concentrated cells; and a step of detecting the desired cells from the detected image, wherein an association is made with the overall survival prognosis diagnosis by counting the detected desired cells, and wherein the desired cells are cells confirmed by the existence of a cell nucleus and in which expression of a leukocyte marker and an epithelial marker is hardly exhibited.

First claim

The invention claimed is:

1. A method of predicting survival prognosis for a cancer diagnosis, comprising:
1) obtaining a concentrated liquid by concentrating target cells from an organism sample obtained from a patient;
2) optically detecting the target cells with flow cytometry or observing the target cells with a microscope or an optical detector and counting target cells contained in the concentrated liquid, the target cells each having cell nucleus and not substantially expressing a leukocyte marker and a CK epithelial marker;
3) determining the number of target cells in the patient based on the number of target cells optically detected in 2), wherein the number of counted target cells is indicative of overall prognosis; and
4) predicting the survival prognosis for the cancer diagnosis by correlating the number of target cells with survival data obtained from a patient's previous prognosis, wherein the survival data comprises a correlation between the number of detected target cells and time period until patient death, and
wherein the cancer is breast cancer, gastric cancer, lung cancer, or oral cancer.

2. The method according to claim 1 , wherein the leukocyte marker is CD45.

3. The method according to claim 1 , wherein the target cells have diameters of not less than 10 μm.

4. The method according to claim 1 , wherein the target cells are circulating tumor cells (CTCs).

5. The method according to claim 1 , wherein the obtaining a concentrated liquid is a concentration method based on a specific gravity difference of a biological sample.

6. The method according to claim 1 , wherein the pretreatment includes concentrating a biological sample using a structure in which one end is closed to form a bottom and the other end has an opening and which has a cap for sealing the opening, and wherein the structure is formed with at least two tubular members such that the structure is separable at a separation unit.

7. The method according to claim 5 , wherein specific gravity of a density gradient solution used in the concentration method is in a range of 1.082 to 1.091 g/mL.

8. The method according to claim 7 , wherein osmotic pressure of a density gradient solution used in the concentration method is in a range of 300 to 400 mOsm/kg.

9. The method according to claim 1 , further comprising 5) treating the patient when the number of target cells is above a predetermined threshold.

10. The method according to claim 9 , wherein the treating comprises administration of anticancer agents, radiation therapy, or surgery on the patient suffering from cancer.

11. The method according to claim 1 , wherein the cancer is lung cancer.

12. The method according to claim 1 , wherein the cancer is breast cancer.

13. The method according to claim 1 , wherein the cancer is oral cancer.

14. The method according to claim 11 , wherein the lung cancer is small cell lung cancer.

15. The method according to claim 11 , wherein the lung cancer is non-small cell lung cancer.

16. The method according to claim 1 , wherein the cancer is gastric cancer.

17. A method of predicting prognosis of a subject having cancer, comprising:
1) obtaining a concentrated liquid by concentrating target cells from an organism sample obtained from the subject;
2) optically detecting the target cells with flow cytometry or observing the target cells with a microscope or an optical detector and counting target cells contained in the concentrated liquid, the target cells each having a cell nucleus and not substantially expressing a leukocyte marker and a CK epithelial marker;
3) determining the number of target cells in the subject based on the number of target cells optically detected in 2), wherein the number of counted target cells is indicative of prognosis; and
4) predicting the prognosis by correlating the number of target cells with prognosis data obtained from cancer patients whose prognosis has previously determined, wherein the prognosis data comprises a correlation between the number of detected target cells and one or more prognosis indicators selected from a group consisting of time period until patient death, the period of pathological progression, cured, relapsed, partial response (PR), complete response (CR), progressive disease (PD), stable disease (SD), and cancer stage, and
wherein the cancer is breast cancer, gastric cancer, lung cancer, or oral cancer.

Assignees

• Tosoh Corp
• Tokyo Metropolitan Government

Inventors

• Akiyama Yasuyuki
• Morimoto Atsushi
• Futami Toru
• Koizumi Fumiaki
• Sawada Takeshi

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/575

  for cancer · CPC title

• G01N2015/0019

  Means for transferring or separating particles prior to analysis, e.g. hoppers or particle conveyors · CPC title

• G01N33/491 Primary

  by separating the blood components (G01N15/05 takes precedence) · CPC title

• G01N33/48735

  Investigating suspensions of cells, e.g. measuring microbe concentration (by chemical means C12Q1/04; colony counters C12M1/34; concentration of particle suspensions in general G01N15/06) · CPC title